RCM Technologies, Inc. — Form 10-Q Summary
Period clarification: The request metadata says 2022 Q3, but the filing is for the 13 and 39 weeks ended September 30, 2023, compared with periods ended October 1, 2022. The interim financial statements are unaudited; amounts below are in U.S. dollars.
Business context and reporting period
RCM provides healthcare staffing and placement, engineering, life sciences, and information technology consulting and project services. Its fiscal quarters follow a 52/53-week calendar. This report covers the third quarter and first 39 weeks of fiscal 2023.
Financial performance
| Metric | 13 weeks ended Sep. 30, 2023 | 13 weeks ended Oct. 1, 2022 | 39 weeks ended Sep. 30, 2023 | 39 weeks ended Oct. 1, 2022 |
|---|---|---|---|---|
| Revenue | $58.0 million | $58.2 million | $192.2 million | $214.5 million |
| Gross profit / margin | $17.3 million / 29.8% | $17.4 million / 29.9% | $55.1 million / 28.6% | $62.5 million / 29.1% |
| Operating income / margin | $4.3 million / 7.5% | $4.8 million / 8.3% | $15.8 million / 8.2% | $22.0 million / 10.3% |
| Net income | $3.8 million | $3.5 million | $11.6 million | $16.1 million |
| Diluted earnings per share | $0.46 | $0.33 | $1.33 | $1.52 |
| Operating cash flow | Not separately presented for the quarter | $27.5 million | $20.7 million |
Third-quarter revenue was essentially flat year over year, while year-to-date revenue fell 10.4%. Year-to-date net income declined 27.9%, and operating margin fell 2.1 percentage points. The quarter’s net income increased despite lower operating income, primarily alongside a lower quarterly tax expense.
Segments and material changes
- Specialty Health Care: Third-quarter revenue declined 11.1% to $24.9 million; 39-week revenue fell 19.5% to $99.6 million. Management attributed the decline chiefly to lower COVID-related demand as activity shifted from pandemic levels to endemic conditions. Year-to-date segment operating income declined to $9.4 million from $15.3 million.
- Engineering: Third-quarter revenue rose 7.3% to $22.5 million, but 39-week revenue was nearly flat at $62.0 million. Lower utilization and margin reduced year-to-date gross profit and operating income. Energy Services growth partly offset declines in Aerospace and Industrial Processing.
- Life Sciences and IT: Third-quarter revenue increased 15.9% to $10.7 million; 39-week revenue rose 5.5% to $30.7 million. Higher margins, which management linked to managed services and, in the quarter, recruitment process outsourcing, lifted segment operating income.
- For the 39-week period, Specialty Health Care generated about 52% of consolidated revenue. One customer accounted for 16.2% of revenue, compared with two customers representing 16.1% and 12.3% in the prior-year period; both periods’ concentrated customers were in Specialty Health Care.
Cash, debt, liquidity, and capital allocation
- At September 30, 2023, cash was $0.7 million, current assets were $73.0 million, and current liabilities were $67.3 million, leaving $5.7 million of positive working capital. Accounts receivable was $57.5 million.
- Operating cash flow of $27.5 million included a $22.4 million cash source from the increase in net transit payables. Management attributed this mainly to large multiyear engineering, procurement, and construction projects with upfront cash funding. Transit payables exceeded transit receivables by $28.9 million at quarter-end; the company notes these balances can fluctuate substantially.
- Investing activities used $0.5 million, including $0.9 million of property and equipment purchases and $0.4 million of asset-sale proceeds. Financing activities used $26.6 million, including $24.4 million of share repurchases.
- Line-of-credit borrowings were $6.7 million, down from $8.8 million at December 31, 2022. The $45 million revolving facility expires April 24, 2026; availability was $36.3 million, after $2.0 million of letters of credit. The weighted-average effective borrowing rate, including unused fees, was 6.4% versus 2.7% in the prior-year period. The facility is secured by substantially all company assets and subsidiary stock; the company reported covenant compliance.
- The company repurchased 1.76 million shares during the 39 weeks for $24.4 million, at an average $13.80 per share. It had $14.3 million remaining under its $25 million repurchase authorization at September 30. Treasury shares increased and stockholders’ equity fell to $21.4 million from $32.0 million at year-end.
- Management said it believes available resources can meet liquidity needs for at least the next 12 months. The filing provides no quantified revenue or earnings guidance.
Outlook, risks, contingencies, and unusual items
- Management describes the business as cyclical and sensitive to economic conditions, customer spending, competition, and demand for outsourced services. It cites staffing and retention, customer concentration and collections, healthcare and employment regulation, insurance claims, foreign exchange, cybersecurity, and litigation among key risks.
- Management expects Healthcare demand to remain above pre-pandemic levels but says the net effect of lower COVID-related activity and other demand is uncertain; it describes the segment as positioned for growth, subject to seasonality. Engineering faces utilization pressure, while Life Sciences and IT reported improved margins.
- The company accrued $2.8 million for asserted claims. For a client dispute involving an Industrial Processing system, it reserved $0.5 million; it believes contractual damages may be capped at $3.3 million and insurance may cover damages subject to a deductible and coverage limit, but gives no assurance on either limit or coverage. Other claims could exceed accrued amounts.
- Estimated acquisition contingent consideration was $2.0 million, including $0.3 million expected within four quarters and $1.7 million thereafter; actual payments may differ. A $0.4 million gain from final collection of escrow related to the 2021 Canada Power Systems divestiture was recorded during the 39-week period.
- Disclosure controls were deemed ineffective at September 30, 2023 due to material weaknesses in IT general controls over SAP access, segregation of duties, and program changes. Management said the weaknesses did not cause a financial-statement misstatement, remediation was in progress, and timing of full remediation remained uncertain.
- The company was upgrading its financial reporting and accounting system, with a planned 2024 go-live and estimated cost of $0.5 million to $1.0 million; the estimate may change.
Most important facts for investors to verify
- Confirm the period: this is fiscal 2023 Q3, not 2022 Q3.
- Track whether Specialty Health Care revenue stabilizes after the post-pandemic decline and whether its customer concentration changes.
- Assess whether operating cash flow remains strong without the unusually large increase in net transit payables, and monitor receivables and project-related working capital.
- Monitor gross and operating margins, especially Engineering utilization and the sustainability of Life Sciences and IT margin gains.
- Review borrowing costs, revolver availability, covenant compliance, and the pace of share repurchases against liquidity needs.
- Follow remediation and independent validation of the disclosed material weaknesses, as well as the legal claims, acquisition earn-outs, and accounting-system upgrade costs.